Artiva Biotherapeutics Inc(ARTV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:25 PM ET (Korea 10/31 05:25)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.31 | Insider Own | 63.55% | Shs Outstand | 48.8M | Perf Week | -31.87% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | 28.24% | Insider Trans | 46.05% | Shs Float | 17.8M | Perf Month | -38.29% |
| Enterprise Value | -0.13B | PEG | - | EPS next Q | -0.55 | Inst Own | 70.49% | Short Float | 15.36% | Perf Quarter | -61.06% |
| Income | -0.09B | P/S | - | EPS this Y | 21.72% | Inst Trans | 41.28% | Short Ratio | 4.58 | Perf Half Y | -61.2% |
| Sales | 0.00B | P/B | 0.59 | EPS next 5Y | 24.88% | ROA | -33.76% | Short Interest | 2.74M | Perf YTD | -2.33% |
| Book/sh | 7.12 | P/C | 0.59 | EPS past 3/5Y | -12.33% -27.38% | ROE | -36.58% | 52W High | -71.16% ($14.53) | Perf Year | 6.35% |
| Cash/sh | 7.15 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.65% | 52W Low | 41.55% ($2.96) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -7.24% | Gross Margin | - | Volatility(W/M) | 5.41% 6.16% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 24.16 | EPS Q/Q | 27.23% | Profit Margin | - | RSI (14) | 20.6 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 24.16 | Sales Q/Q | - | SMA20 | -30.42% ($6.02) | Beta | 2.47 | Target Price | $20.75 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/6 | SMA50 | -48.35% ($8.11) | Rel Volume | 3.29 | Prev Close | $4.23 |
| Employees | 104 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -0.78% - | SMA200 | -47.79% ($8.03) | Avg Volume(3M) | 0.60M | Price | $4.19 |
| IPO | 2024/7/19 | Option/Short | Yes/Yes | Trades | 8563 | Volume | 1,966,079 | Change | -0.95% |
🧬 Ativa Biotherapeutics (ARTV) is a US-based clinical-stage biotech company developing allogeneic natural killer (NK) cell therapies. Its lead candidate, AlloNK, is an "off-the-shelf" NK cell therapy that is cryopreserved and ready for immediate use without separate genetic modification, and is designed to work in combination with antibodies (such as anti-CD20 monoclonal antibodies) to achieve deep B-cell depletion. The company's primary targets are B-cell–mediated autoimmune diseases, including rheumatoid arthritis and lupus.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded more than usual. That is 329% of its average volume.
ARTV has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +21.7% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 70.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #298 of 597 in the industry
Based on market cap of $205M.
KRRO#295 Korro Bio Inc $211M PER - 
BBOT#296 BridgeBio Oncology Therapeutics Inc $210M PER - 
PLX#297 Protalix BioTherapeutics Inc $209M PER 11.4 ARTV#298 Artiva Biotherapeutics Inc $205M PER - 
PALI#299 Palisade Bio Inc $202M PER - 
FAQ
What kind of company is ARTV?
ARTV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ARTV?
The market cap of ARTV is approximately $205M, ranking 3,986 within its sector.
What is the 52-week high and low for ARTV?
ARTV has recorded a 52-week high of $14.53 and a low of $2.96.
